Patient quality of life has been shown to be severely impaired by the associated ocular surface symptoms, so treatment aims for symptomatic relief and prevention of further damage to the ocular ...
Open-access OCTA tools showed similar reliability, but different vessel density values in glaucoma; researchers advise using ...
Drs Bryce St. Clair and Behrad Garmsiri explain how they build trust, improve health literacy, and destigmatize future ...
The release noted that brepocitinib demonstrated consistent benefits in preventing treatment failure across key subgroups, ...
Dr. Caldwell is an ocular disease consultant based in Johnstown, Pennsylvania. His primary focus is the diagnosis and management of anterior and posterior segment ocular disease, and he has been a ...
From dry eye to GLP-1s, this year's conference brought a variety of insights from key experts in optometry. Want more ...
The Nobel Assembly at Karolinska Institutet announced that the 2026 Nobel Prize in Physiology or Medicine will be shared ...
Interim 48-month data show 86% of patients with glaucoma or ocular hypertension remain off topical drops after a single cataract procedure, although the drop-free rate has eased from earlier ...
Ryzumvi (phentolamine ophthalmic solution 0.75%) is approved for the treatment of presbyopia in adults. It is also approved for pharmacologically induced mydriasis produced by adrenergic agonists or ...
The US FDA Dermatologic and Ophthalmic Drugs Advisory Committee will meet October 30, 2026, to review new drug application ...
Alcon's Brytly eye drops received FDA approval for OTC temporary relief of minor ocular redness. Alcon has received FDA approval for apraclonidine ophthalmic solution 0.125% (Brytly) redness relief ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results